Business Description
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Share Class Description:
CORT: Ordinary SharesDescription
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5404.75 | |||||
| Equity-to-Asset | 0.84 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 18.56 | |||||
| Beneish M-Score | -2.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.9 | |||||
| 3-Year EBITDA Growth Rate | -2.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.4 | |||||
| 3-Year FCF Growth Rate | -2.2 | |||||
| 3-Year Book Growth Rate | 3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 25.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.09 | |||||
| 9-Day RSI | 74.82 | |||||
| 14-Day RSI | 68 | |||||
| 6-1 Month Momentum % | -4.91 | |||||
| 12-1 Month Momentum % | -0.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.18 | |||||
| Quick Ratio | 5.1 | |||||
| Cash Ratio | 4.23 | |||||
| Days Inventory | 342.06 | |||||
| Days Sales Outstanding | 28.22 | |||||
| Days Payable | 629.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4 | |||||
| Shareholder Yield % | 0.06 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.54 | |||||
| Operating Margin % | 23.29 | |||||
| Net Margin % | 22.54 | |||||
| FCF Margin % | 23.85 | |||||
| ROE % | 23.92 | |||||
| ROA % | 19.58 | |||||
| ROIC % | 69.46 | |||||
| ROC (Joel Greenblatt) % | 22858.83 | |||||
| ROCE % | 24.21 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.51 | |||||
| Forward PE Ratio | 37.77 | |||||
| PE Ratio without NRI | 25.51 | |||||
| Shiller PE Ratio | 38.63 | |||||
| Price-to-Owner-Earnings | 35.6 | |||||
| PEG Ratio | 4.72 | |||||
| PS Ratio | 5.7 | |||||
| PB Ratio | 5.13 | |||||
| Price-to-Tangible-Book | 5.13 | |||||
| Price-to-Free-Cash-Flow | 23.9 | |||||
| Price-to-Operating-Cash-Flow | 23.9 | |||||
| EV-to-EBIT | 19.36 | |||||
| EV-to-EBITDA | 19.1 | |||||
| EV-to-Revenue | 4.51 | |||||
| EV-to-Forward-Revenue | 3.69 | |||||
| EV-to-FCF | 18.91 | |||||
| Price-to-Projected-FCF | 1.22 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Graham-Number | 2.41 | |||||
| Price-to-Net-Current-Asset-Value | 7.12 | |||||
| Price-to-Net-Cash | 9.29 | |||||
| Earnings Yield (Greenblatt) % | 5.17 | |||||
| FCF Yield % | 4.43 | |||||
| Forward Rate of Return (Yacktman) % | 7.69 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers